Market Cap | 72.60M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -17.55M | Forward P/E | -3.74 | EPS next Y | - | 50D Avg Chg | -21.00% |
Sales | 33.34M | PEG | - | EPS past 5Y | -24.05% | 200D Avg Chg | -22.00% |
Dividend | N/A | Price/Book | 3.83 | EPS next 5Y | - | 52W High Chg | -47.00% |
Recommedations | - | Quick Ratio | 2.82 | Shares Outstanding | 51.46M | 52W Low Chg | 46.00% |
Insider Own | 24.08% | ROA | -12.77% | Shares Float | 39.43M | Beta | 0.73 |
Inst Own | 31.99% | ROE | -39.90% | Shares Shorted/Prior | 478.73K/507.80K | Price | 1.46 |
Gross Margin | 43.66% | Profit Margin | 134.17% | Avg. Volume | 256,006 | Target Price | - |
Oper. Margin | -25.47% | Earnings Date | Nov 4 | Volume | 165,104 | Change | 0.00% |
Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.
Craig-Hallum | Buy | Feb 4, 14 |
Sidoti & Co. | Neutral | Jul 2, 13 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Wolf James G. | Other Other | Feb 10 | Buy | 1.29 | 15,000 | 19,350 | 115,000 | 02/13/23 |
Wolf James G. | 10% Owner 10% Owner | Jan 27 | Buy | 1.4 | 11,800 | 16,520 | 4,090,000 | 01/30/23 |
Wolf James G. | 10% Owner 10% Owner | Oct 31 | Buy | 2.15 | 23,000 | 49,450 | 418,500 | 01/19/23 |
Wolf James G. | 10% Owner 10% Owner | Oct 31 | Buy | 2.15 | 23,000 | 49,450 | 418,500 | 01/18/23 |
Erfanian Hamid | Chief Executive Offi.. Chief Executive Officer | Nov 23 | Buy | 1.97 | 100,000 | 197,000 | 374,600 | 11/28/22 |
Cannon Kara | Chief Operating Offi.. Chief Operating Officer | Jul 15 | Buy | 2.42 | 2,500 | 6,050 | 2,500 | 07/19/22 |
Radoff Bradley Louis | Director Director | Jul 12 | Buy | 2.27 | 12,500 | 28,375 | 4,194,663 | 07/13/22 |
Radoff Bradley Louis | Director Director | Jul 05 | Buy | 2.20 | 120,000 | 264,000 | 4,182,163 | 07/06/22 |
Radoff Bradley Louis | Director Director | Jun 15 | Buy | 2.21 | 125,000 | 276,250 | 3,987,163 | 06/16/22 |